McKesson Q2 FY27: EPS $10.44, Revenue $111.0B; Debt Jumps to $9.2B on MMS Term Loans
MCK sits 47% above its 52-week low of $723.68.
Summary
McKesson's Q2 FY27 revenue rose 8% to $110,957 million and diluted EPS jumped to $10.44 from $8.92, while total debt rose to $9,208 million on $3.2 billion of Medical-Surgical Solutions term loans and the company closed roughly $2.8 billion of acquisitions in early November.
Key Events · Earnings and Guidance · MCK
-
Q2 Revenue Up 8%, EPS $10.44
Revenue rose to $110,957 million from $103,150 million and diluted EPS to $10.44 from $8.92; gross profit grew 12% to $3,956 million.
-
Debt Climbs to $9.2B
Total debt rose to $9,208 million from $6,526 million after $3.2 billion of Medical-Surgical Solutions term loans; quarterly interest expense rose 42% to $105 million.
-
Acquisitions Closed and Pending
Closed Precision Medicine Group for about $2.25 billion and a Spectrum Vision Partners controlling stake for about $525 million in early November; agreed October 5 to buy a 49% Option Care Health stake for about $1.4 billion, expected to close in the first half of calendar 2027.
-
Noncontrolling Interests Cut Net Income
Six-month net income attributable to McKesson fell to $1,832 million from $1,894 million as $496 million went to noncontrolling interests, including a $391 million redemption-value adjustment.
Analysis · MCK · Trade & Services
The quarter was strong — revenue up 8% to $110,957 million and diluted EPS up 17% to $10.44 — but the balance sheet is where the story changed. Total debt climbed to $9,208 million from $6,526 million at March 31 after the Medical-Surgical Solutions unit took on $3.2 billion of term loans, pushing interest expense up 42% to $105 million for the quarter. McKesson also closed roughly $2.25 billion for Precision Medicine Group and about $525 million for a controlling stake in Spectrum Vision Partners in early November, and agreed on October 5 to pay about $1.4 billion for a 49% stake in Option Care Health alongside CD&R, expected to close in the first half of calendar 2027. Six-month net income attributable to McKesson slipped to $1,832 million from $1,894 million because $496 million went to noncontrolling interests, including a $391 million redemption-value adjustment tied to the Apollo investment in Medical-Surgical Solutions. Restructuring charges doubled to $221 million for the six months, and the opioid litigation liability came down to $5,163 million after $496 million of payments.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCK was trading at $1,060.30 on NYSE in the Trade & Services sector, with a market capitalization of approximately $124.7B. The 52-week trading range was $723.68 to $1,073.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.